[1] 徐永康,付舒敏,李丹,等.肝动脉灌注化疗联合系统治疗在原发性肝癌中的研究进展[J].介入放射学杂志,2023,32(1):94-97. [2] 贾浪,李有赞,朱世凯,等.肝动脉灌注化疗联合PD-1抗体及仑伐替尼治疗晚期肝癌合并门静脉癌栓的临床研究[J].实用医院临床杂志,2022,19(5):163-167. [3] 柯映平,叶绍光,卢舜彬.肝动脉化疗栓塞术联合FOLFOX方案持续性动脉灌注化疗在巴塞罗那B期原发性肝癌患者中的应用效果[J].中国当代医药,2022,29(18):73-76. [4] 张炎锋,苗炜宇,景静源.肝动脉灌注化疗(HAIC)栓塞对原发性肝癌介入治疗效果及对患者血清指标与生活质量的影响[J].医药论坛杂志,2022,43(9):80-83. [5] 丛文铭,步宏,陈杰,等.原发性肝癌规范化病理诊断指南(2015年版)[J].解放军医学杂志,2015,40(11):865-872. [6] 柳彬,李智颖.顺铂热灌注化疗联合肝动脉灌注化疗栓塞术治疗肝细胞癌患者的效果[J].中国民康医学,2023,35(3):24-27. [7] 游宇来,徐凌翔,龚建平.TACE联合肝动脉留置导管灌注化疗治疗肝细胞肝癌1例及文献复习[J].临床医学研究与实践,2021,6(36):18-20,88. [8] 冯丽娟,谢建立,花雪娇.索拉非尼联合肝动脉灌注化疗治疗对晚期肝癌患者肝功能指标及生活质量改善状况的影响[J].中国医学创新,2021,18(21):24-28. [9] 何翠瑛,苏贞栋,陈燕红,等.阿帕替尼联合TACE治疗原发性肝癌复发生存的影响因素分析[J].中西医结合肝病杂志,2023,33(4):298-302. [10] 宋奇锋,胡玲,林师佈,等.肝动脉灌注化疗与肝动脉灌注化疗栓塞术治疗Ⅱ_b-Ⅲ_a期肝细胞癌的近远期疗效比较[J].现代肿瘤医学,2023,31(8):1476-1480. [11] CHUNG J W.Hepatic Arterial Infusion Chemotherapy for Advanced Hepatocellular Carcinoma in the Era of New Systemic Agents[J]. Radiology,2022,303(2):465-466. [12] WU Z Q, GAO J, ZHUANG W Q, et al.Efficacy and safety of transcatheter arterial chemoembolization plus hepatic arterial infusion chemotherapy in the treatment of advanced hepatocellular carcinoma with portal vein tumor thrombosis in the main trunk[J]. Journal of Cancer Research and Therapeutics,2022,18(2):345-351. [13] YOU H M, LIU X Y, GUO J D, et al.Hepatic arterial infusion chemotherapy and sequential ablation treatment in large hepatocellular carcinoma[J]. International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group,2022,39(1):1097-1105. |